| | | Analyst Ratings Snapshot (as of November 2025)- DA Davidson
- Maintains a Buy rating.
- Recently raised its price target to $12 (from $11), citing upside from the Montana tungsten project and stronger tungsten pricing.
- Oppenheimer
- Rates Almonty Outperform (Buy).
- Boosted target price from $7 to $12, reflecting confidence in Sangdong’s near-term production and global tungsten demand.
- Cantor Fitzgerald
- Initiated coverage with an Overweight (Buy) rating.
- Target price: $6.50, more conservative but still bullish.
- Wall Street Zen (via MarketBeat)
- Upgraded Almonty from Sell to Hold on Nov 8, 2025.
- Notes balance sheet risks (high debt-to-equity ratio) but acknowledges improved outlook.
- Weiss Ratings
- Still lists Almonty as Sell (E+), citing negative margins and high leverage.
- Consensus (MarketScreener)
- Average rating: Moderate Buy.
- Consensus target price: ~$9.83, with upside potential from current ~$7 trading levels.
Key Themes in Analyst Framing- Bullish arguments (Buy/Outperform):
- Strong Q3 turnaround (CAD 33M net income).
- Sangdong mine in South Korea nearing commissioning.
- Montana acquisition adds U.S. tungsten exposure.
- Rising tungsten prices and geopolitical demand for non-Chinese supply.
- Bearish/Cautious arguments (Sell/Hold):
- High debt-to-equity ratio (~16.4).
- Negative EBITDA and thin margins in recent quarters.
- Dilution concerns from past financings.
- Volatility after lock-up expiration.
Takeaway for Investors- Most analysts see Almonty as a Buy, with targets ranging from $6.50 to $12, suggesting upside from current levels.
- Consensus is “Moderate Buy”, but the split ratings (Buy vs. Sell) show that risk factors—especially debt and execution at Sangdong—remain front of mind.
- The stock is framed as a high-risk/high-reward play: if Sangdong and Montana deliver, Almonty could become a dominant Western tungsten supplier; if delays or financing issues persist, downside remains.
|
|
